ASH airing a further reminder of argenx' 'pipeline in a product'

Autoimmune diseases specialist argenx (Nasdaq: ARGX) has previously referred to Vyvgart (efgartigimod alfa-fcab), an antibody fragment that binds to the neonatal Fc receptor (FcRn), as a ‘pipeline in a product’.

The Belgo-Dutch company had a further chance to demonstrate this with a presentation in the plenary session at the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans over the weekend.

This presentation was on data from argenx’ Phase III ADVANCE study, the first of two registrational trials evaluating the efficacy, safety and tolerability of Vyvgart for the treatment of adults with primary ITP, this time the intravenous formulation.